Introduction. Weighing the Evidence: Weight Management Insights for Treating Major Mental Illness

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Second-generation antipsychotics (SGAs), or "atypical" antipsychotics, have become the dominant treat ment choice for patients with schizophrenia and have alsobeen used as monotherapy and in combination therapy with lithium and anticonvulsants in the treatment of bipolar disorder. The advantage of SGAs over the older "neuroleptics" has principally been in their lower propensity for extrapyramidal side effects, including tremor, rigidity, and akathisia. Also, evidence has shown that SGAs have a broad spectrum of therapeutic action regarding negative symptoms, including mood dysregulation, hostility, cognitive dysfunction, and comorbid alcohol and substance abuse.¹‘ ‹’ ‹